About: Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic. It is also developing RAD301 and RAD302, which are Avß6-Integrin pancreatic diagnostic and therapeutic products; RAD401, a PSA-mAb prostate cancer diagnostic; and RAD402, a PSA-mAb prostate cancer therapeutic. The company was incorporated in 2021 and is based in Carlton, Australia.
Sector: Healthcare
Industry: Biotechnology
Latest price: $1.15 (-2.54%)
RADX NASDAQ Radiopharm Theranostics Limited American Depositary Shares
Radiopharm Theranostics Limited American Depositary Shares share price
RADX price activity
Last Price
$1.150
Change (24hr)
-0.03 USD (-2.54%)
Volume
42.09K
Volume (4w avg)
-
Open
$1.18
Day Range
$1.13 - $1.19
Previous Close
$1.18
Last Trade
07 Oct, 8:00 pm GMT+0
Delayed
07 Oct, 8:00 pm GMT+0
RADX price performance
Delayed
07 Oct, 8:00 pm GMT+0
RADX Market Signals